合作
AstraZeneca licenses oral EGFR inhibitor Zegfrovy from Dizal in up to $1.5B deal
AstraZeneca entered an exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral EGFR inhibitor for EGFR exon 20 insertion NSCLC. AstraZeneca will pay $600 million upfront and up to $900 million in milestones plus tiered royalties for worldwide rights.
大盤 開啟原文 ↗